[ACS] Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

 Close Closed
zykkd Post time 2026-5-7 15:40:17 | Show all posts |Read mode
Reward10points

journalㄩJournal of Medicinal Chemistry

AuthorsㄩJames Cregg; Kristof Pota; Aidan C. A. Tomlinson; Jason Yano; Abby Marquez; Yang Liu; Christopher J. Schulze; Kyle J. Seamon; Matthew Holderfield; Xing Wei; Yongxian Zhuang; Yu Chi Yang; Jingjing Jiang; Yue Huang; Ruiping Zhao; Yun Ling; Zhican Wang; Michael Flagella; Zhengping Wang; Mallika Singh; John E. Knox; Robert Nichols; David Wildes; Jacqueline A. M. Smith; Elena S. Koltun; Adrian L. Gill

Published dateㄩ2025-3-27

DOIㄩ10.1021/acs.jmedchem.4c02313

PDF linkㄩhttps://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c02313

Article linkㄩhttps://doi.org/10.1021/acs.jmedchem.4c02313

Article SourceㄩAmerican Chemical Society (ACS)


Remarkㄩ
Reply

Use magic Donate Report

All Reply1 Show all posts
Georgee Post time 2026-5-7 15:40:17 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply
zykkd Post time 2026-5-7 15:41:29 | Show all posts

Waiting for confirmation

If the PDF has not been accepted after 72 hours, the system will automatically adopt it.
Reply

Use magic Donate Report

Junior Member
  • post

  • reply

  • points

    30


Daily Top Contributors

Return to the list